Radka Obermannova
Overview
Explore the profile of Radka Obermannova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kroese T, Bronzwaer S, van Rossum P, Schoppman S, Deseyne P, Van Cutsem E, et al.
Eur J Cancer
. 2024 Apr;
204:114062.
PMID: 38678762
Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods: Guidelines were developed according to...
2.
Kroese T, van Laarhoven H, Schoppman S, Deseyne P, Van Cutsem E, Haustermans K, et al.
Eur J Cancer
. 2023 Mar;
185:28-39.
PMID: 36947929
Background: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic...
3.
Ben-Aharon I, van Laarhoven H, Fontana E, Obermannova R, Nilsson M, Lordick F
Cancer Discov
. 2023 Feb;
13(3):538-551.
PMID: 36757194
Significance: The worrisome trend of an increasing incidence of early-onset gastrointestinal cancers appears to be correlated with nonhereditary etiologies in which behavioral, lifestyle, nutritional, microbial, and environmental factors, as well...
4.
Moehler M, Hogner A, Wagner A, Obermannova R, Alsina M, Thuss-Patience P, et al.
Eur J Cancer
. 2022 Oct;
176:13-29.
PMID: 36183651
The new era of immunotherapy is successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been investigated in combinations with/without chemotherapy in human epidermal growth...
5.
Pavlakis N, Tincknell G, Lim L, Muro K, Obermannova R, Lorenzen S, et al.
Ther Adv Med Oncol
. 2022 Sep;
14:17588359221118874.
PMID: 36051471
Gastric carcinoma and gastro-oesophageal junction (GC/GEJ) carcinoma remain a significant global problem, with patients presenting with symptoms often found to have advanced or metastatic disease. Treatment options for these patients...
6.
Sclafani F, Fontana E, Wyrwicz L, Wagner A, Valle J, Smyth E, et al.
Clin Colorectal Cancer
. 2022 May;
21(3):188-197.
PMID: 35637095
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to...
7.
Kroese T, van Hillegersberg R, Schoppmann S, Deseyne P, Nafteux P, Obermannova R, et al.
Eur J Cancer
. 2022 Feb;
164:18-29.
PMID: 35134666
Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in...
8.
Lordick F, Obermannova R, Smyth E
Lancet Oncol
. 2022 Jan;
23(2):188-190.
PMID: 35038428
No abstract available.
9.
Obermannova R, Selingerova I, rehak Z, Jedlicka V, Slavik M, Fabian P, et al.
Ther Adv Med Oncol
. 2022 Jan;
13:17588359211065153.
PMID: 35035533
Background: Perioperative chemotherapy is a recommended treatment approach for localised oesophago-gastric junction adenocarcinoma, but not all patients respond to neoadjuvant chemotherapy. Early identification of non-responders and treatment adaptation in the...
10.
Slavik M, Burkon P, Selingerova I, Krupa P, Kazda T, Stankova J, et al.
Medicina (Kaunas)
. 2021 Dec;
57(12).
PMID: 34946279
: The treatment of gastroesophageal junction (GEJ) adenocarcinoma consists of either perioperative chemotherapy or preoperative chemoradiotherapy. Radiotherapy (RT) in the neoadjuvant setting is associated with a higher probability of resections...